Turnstone Biologics Corp. (TSBX)
NASDAQ: TSBX · IEX Real-Time Price · USD
2.700
0.00 (0.00%)
At close: Jun 17, 2024, 4:00 PM
2.720
+0.020 (0.74%)
Pre-market: Jun 18, 2024, 7:12 AM EDT
Turnstone Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Turnstone Biologics stock have an average target of 19, with a low estimate of 18 and a high estimate of 20. The average target predicts an increase of 603.70% from the current stock price of 2.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 15, 2023.
Analyst Ratings
The average analyst rating for TSBX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Aug '23 |
---|---|
Strong Buy | 1 |
Buy | 1 |
Hold | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
B of A Securities | B of A Securities | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +566.67% | Aug 15, 2023 |
Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +640.74% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
n/a
from 19.31M
Revenue Next Year
n/a
EPS This Year
-3.51
from -4.78
EPS Next Year
-2.61
from -3.51
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | n/a | n/a |
Avg | n/a | n/a | n/a | n/a | n/a |
Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -3.02 | -2.49 | -3.14 |
Avg | -3.51 | -2.61 | -3.05 |
Low | -4.40 | -2.69 | -2.93 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.